Veru (NASDAQ:VERU) Posts Earnings Results, Beats Expectations By $0.02 EPS

Veru (NASDAQ:VERU) released its quarterly earnings data on Monday. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.02, FiscalAI reports.

Here are the key takeaways from Veru’s conference call:

• PLATEAU trial fully enrolled with 239 older patients receiving semaglutide and enobosarm; the 32-week interim analysis is expected in Q1 2027, with final results targeted for Q4 2027.
• Veru received a USPTO notice of allowance for enobosarm’s use with semaglutide and other weight-loss drugs to preserve lean mass, enhance fat loss, and improve physical function, with potential patent protection through at least October 2044.
• Novo Nordisk will supply Wegovy at no charge for the PLATEAU study, while Veru retains global enobosarm rights; the agreement also gives Novo Nordisk a right of first negotiation for future combinations with its GLP-1 products.
• Management is positioning enobosarm for older patients with obesity at risk of muscle and physical-function decline from GLP-1 treatment, citing a potential Medicare population of more than 20 million people, though commercial opportunity remains dependent on clinical and regulatory success.
• Veru remains unprofitable and used $20.6 million in operating cash during the first nine months of fiscal 2026; its $23.9 million cash and restricted-cash balance is expected to fund operations only beyond the PLATEAU interim analysis, indicating possible future financing needs.

Veru Price Performance

Shares of NASDAQ VERU opened at $2.77 on Tuesday. The stock has a market capitalization of $44.46 million, a P/E ratio of -3.11 and a beta of -1.15. Veru has a 1-year low of $2.05 and a 1-year high of $7.33. The business has a fifty day moving average price of $2.72 and a 200 day moving average price of $2.50.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Veru during the 3rd quarter valued at $38,000. Jacobs Levy Equity Management Inc. purchased a new stake in Veru in the third quarter valued at about $110,000. ADAR1 Capital Management LLC purchased a new stake in Veru in the fourth quarter valued at about $75,000. Blair William & Co. IL grew its stake in shares of Veru by 26.3% during the fourth quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock worth $103,000 after acquiring an additional 10,000 shares during the last quarter. Finally, NewEdge Advisors LLC raised its position in shares of Veru by 388.7% in the 4th quarter. NewEdge Advisors LLC now owns 70,525 shares of the company’s stock valued at $151,000 after purchasing an additional 56,095 shares during the last quarter. Institutional investors own 47.16% of the company’s stock.

Wall Street Analyst Weigh In

VERU has been the topic of a number of recent research reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $25.00 target price on shares of Veru in a report on Thursday, June 4th. Oppenheimer reduced their price objective on shares of Veru from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Weiss Ratings raised shares of Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen upgraded Veru to a “hold” rating in a research report on Sunday, July 12th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Veru currently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.